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BACKGROUND: There is no consensus agreement regarding optimal management of locally excised ductal carcinoma in situ (DCIS) or
features of greatest assistance in predicting disease behaviour. Cases in the UKCCCR/ANZ DCIS trial have been histologically
reviewed to determine the features of prognostic importance.
METHOD: A total of 72% of 1694 cases entered into the UKCCCR/ANZ DCIS trial had full pathological review. A large number of
histological features were assessed, blinded to outcome and compared regarding ability to predict ipsilateral recurrence, as either
DCIS or progression to invasive carcinoma.
RESULTS: Pathological features associated with ipsilateral recurrence in univariate analysis included high cytonuclear grade, larger lesion
size, growth pattern, presence of necrosis or chronic inflammation, incompleteness (or uncertainty of completeness) of excision and
smaller margin width. Receipt of post-operative radiotherapy was also a strong prognostic factor.
We report a novel sub-division of the large group of high-grade lesions, which enables identification of a very poor prognosis sub-
group; namely, DCIS that is of high cytonuclear grade, predominantly (450%) solid architecture, bearing extensive comedo-type
necrosis (450% of ducts). In addition, we found little difference in ipsilateral recurrence rates between low- and intermediate-grade
groups. Hazard ratios for low, intermediate, high and the new, very high, grade were 0.42, 0.33, 0.62 and 1.00, respectively, for
ipsilateral in situ or invasive recurrence.
CONCLUSION: We present a novel pathological classification for DCIS with substantially better prognostic discrimination for ipsilateral
recurrence than the classical categorisation based on cytonuclear grade alone.
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Mammographic breast screening facilitates the diagnosis of ductal
carcinoma in situ (DCIS) (Anderson et al, 1991) and the apparent
incidence has increased as a result (Baxter et al, 2004). Thus, DCIS
comprised 21% of screen-detected breast carcinoma in the United
Kingdom in 2006–2007 (NHS Breast Screening Programme.
Annual Review, 2008). In the early 1990s, three large randomised
clinical trials began recruiting with the aim of assessing the
safety of breast conserving surgery (BCS) for DCIS and the
requirement for subsequent radiotherapy (RT) in women having
wide local excision (WLE) for DCIS. The NSABP B-17 (Fisher et al,
1998, 1999b) and EORTC 10853 trials (Julien et al, 2000;
Bijker et al, 2001, 2006), as well as the UKCCCR/ANZ DCIS trial
(UK Coordinating Committee on Cancer Research Ductal
Carcinoma in situ Working Party, 2003) recruited patients
diagnosed with DCIS in the early 1990s and have already presented
results comparing complete surgical excision with and without
RT. Two of these trials (Fisher et al, 1999a; UK Coordinating
Committee on Cancer Research Ductal Carcinoma in situ Working
Party, 2003) also addressed the effect of the addition of tamoxifen
to complete local excision in the management of DCIS.
The clinical management of patients with DCIS changed during
the 1990s, but, despite the large reduction of local recurrence risk
from RT after BCS for DCIS, only 57% of women have RT after
BCS in the United Kingdom (Dodwell et al, 2007). There is a
widespread belief that not all patients with DCIS require RT.
However, the search for features that can assist in this clinical
decision-making process remains unresolved (Silverstein et al,
1996; Sakorafas and Farley, 2003).
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sMATERIALS AND METHODS
The UKCCCR DCIS trial was a 2 2 factorial randomised clinical
trial comparing complete WLE alone with WLE plus RT to the
residual ipsilateral breast tissue. Two further arms consisted
of WLE followed by tamoxifen and WLE plus RT and tamoxifen.
The dose of tamoxifen was 20mg daily taken for 5 years. Patients
receiving RT were given supervoltage treatment with opposed
tangential fields that included the breast and the axillary tail.
A dose of 50Gy in 25 fractions over 5 weeks was suggested.
No boost was recommended.
Patients had unilateral or bilateral DCIS detected through the
UK National Health Service Breast Screening Programme, which
was considered suitable for BCS. The Australian–New Zealand
Breast Cancer Trials Group also participated in the trial. Patients
with microinvasive carcinoma (o1mm in maximum dimension)
were eligible for inclusion. Exclusion criteria included a diagnosis
of atypical ductal hyperplasia, lobular carcinoma in situ or Paget’s
disease of the nipple. Patients gave witnessed, written or verbal
consent for inclusion, and local ethics approval was obtained in all
centres recruiting patients.
After randomisation and treatment, patients were followed up as
per local protocol. Dates of relapse (ipsilateral or contralateral),
diagnosis of new, non-breast malignant disease and death (breast
cancer-related or not) were recorded.
Histological review
Representative material was sought from the surgical excision.
Slides were examined by a single breast pathologist (SEP) and a
large number of histological features were recorded in a database
(see Table 1). Any cases that on review showed histological
features, which were not sufficient for the diagnosis of DCIS, or
which showed an invasive focus, were reviewed and the diagnosis
confirmed by a second pathologist (IOE).
Features recorded
The histological features of DCIS assessed are shown in Table 1.
For some of these, criteria had to be specifically defined as, after
literature and guideline review, it was found that no globally
agreed definitions could be applied. For example, for the purposes
of this study, comedo DCIS was defined specifically as (i) high-
grade DCIS with (ii) central confluent necrosis and (iii) solid
architectural pattern in 450% of the involved duct spaces. All
these features had to be present for classification of pure comedo
Table 1 Univariate analysis – recurrence of ipsilateral DCIS or invasive disease
Feature Categories No. cases No. events HR (95% CI) v
2 for trend P-value
Cytonuclear grade (National Pathology
Co-ordinating Group, 2005)
Low 86 6 0.51 (0.22–1.15) 14.58
Intermediate 225 13 0.41 (0.23–0.72) P¼0.0007
High 913 135 1.00
a
Traditional/historical nomenclature Small cell micropapillary 17 3 1.32 (0.42–4.16) 39.34
Small cell cribriform 86 0 0 (0.00–0.20) Po0.0001
Small cell solid 31 3 0.53 (0.17–1.68)
Small cell mixed 65 7 0.63 (0.29–1.37)
Large cell mixed 298 31 0.60 (0.40–0.90)
Large cell cribriform 130 10 0.41 (0.21–0.80)
Large cell solid 86 11 0.75 (0.40–1.40)
Comedo 483 88 1.00
a
Papillary 28 1 0.20 (0.03–1.45)
Van Nuys grade (Silverstein et al, 1995) Non-high grade without necrosis 99 5 0.39 (0.16–0.94) 14.58
Non-high grade with necrosis 212 14 0.45 (0.26–0.78) P¼0.0007
High 913 135 1.00
a
Nottingham grade (Poller et al, 1994) DCIS without necrosis 117 6 0.58 (0.25–1.35) 19.38
Non-pure comedo 624 88 1.00
a P¼0.0001
Comedo 483 60 1.85 (1.33–2.57)
Differentiation (Holland et al, 1994) Well differentiated 90 6 0.38 (0.22–0.66) 18.09
Moderately differentiated 248 14 0.47 (0.21–1.07) P¼0.0001
Poorly differentiated 886 134 1.00
a
Main architecture Solid 731 111 1.00
a 15.14
Cribriform 372 27 0.47 (0.31–0.71) P¼0.002
Micropapillary 91 13 0.97 (0.54–1.71)
Papillary 30 3 0.50 (0.20–2.02)
Necrosis Confluent comedo necrosis present 1107 147 1.00
a 4.07
Confluent comedo necrosis not present 117 7 0.50 (0.23–1.06) P¼0.04
Age 450years
a 1132 137 1.00
a 3.74
p50years 92 17 1.71 (1.03–2.82) P¼0.05
Chronic inflammation associated with DCIS Present 924 135 1.00
a 12.78
Not present 296 19 0.45 (0.27–0.73) Po0.0001
Histological calcification Present 1089 135 1.00
a 1.11
Not present 129 19 1.31 (0.81–2.11) NS
Tumour size 0–0.9cm 368 27 0.55 (0.35–0.85) 20.04
1.0–1.9cm 575 77 1.00
a Po0.0001
42.0cm 268 49 1.55 (1.08–2.22)
Excision Complete (1mm or more from margin) 846 91 1.00
a 7.77
Incomplete (DCISo1mm from margin) 196 31 1.50 (1.00–2.26) P¼0.02
Uncertain 182 32 1.67 (1.12–2.50)
Abbreviations: CI¼confidence interval; DCIS¼ductal carcinoma in situ;H R¼hazard ratio.
aBaseline category. Cases with missing values for a variable have been excluded from
that analysis.
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sdisease in both the traditional sub-type categorisation and for
‘Nottingham’ DCIS grade.
The original clinical protocol for the UKCCCR DCIS trial
required complete excision of DCIS, but no margin width was
defined. Review of completeness of excision and margin width is
problematic within the auspices of a central pathology view.
However, the evaluation of margin status and distance was
determined on a case-by-case basis, taking into account the
original histology report, number and orientation of specimens
and the histological review, in which the distance (mm) to the
nearest margin was measured on the histological sections received
using the Vernier scale of the microscope. For the purposes of the
present analysis, a distance of 1mm or more from the nearest
margin was defined as complete excision. Thus, if DCIS was stated
to be 1mm or more from the surgical margin (or completely
excised) in the original report, and this was confirmed on review,
excision was deemed complete. Excision was recorded as
incomplete if DCIS extended to o1mm from the margin in the
original histology report (or was stated to be incompletely excised)
and in the reviewed slides. Excision was coded as uncertain, when
multiple pieces of unorientated tissue were received by the original
pathologist or excision was stated as uncertain in original report
(and no subsequent surgical procedure undertaken) or there was a
discrepancy between the review and original report that could not
be explained taking all features into account.
For determination of size of DCIS, the larger of the measure-
ments of maximal dimension from either the original report or
review of histological sections was recorded. If there was DCIS in
first and any subsequent re-excision, or several pieces of tissue
were excised bearing DCIS, the measurements were summed
(recognising that this would be an approximation and would
generally be an overestimate of total size). In some cases, size
could not be assessed on review and was not recorded in the
original histology report.
The presence and degree of associated chronic inflammation
was recorded. This was typically immediately adjacent to the
involved ducts spaces and some cases included nodular aggregates
of lymphoid cells, with lymphoid follicle formation. In other cases,
this was seen as a complete, targetoid, peri-ductal population of
lymphoid cells. This was assessed in a semi-quantitative manner
and scored as absent, mild, moderate or marked.
RESULTS
Treatment comparison analyses have been presented earlier (UK
Coordinating Committee on Cancer Research Ductal Carcinoma
in situ Working Party, 2003). Here, we present results from the
histological review with the same follow-up. Between May
1990 and August 1998, 1701 patients were entered into the trial.
Seven were excluded because of protocol violations (earlier
malignant disease, treated by mastectomy, known to have invasive
carcinoma) (n¼1694 patients in total in the trial overall).
The number of slides submitted for pathological review
varied (range 0–64 per case), with some laboratories submitting
all slides, whereas others sent one representative slide or block
(total number of sections 9649, mean 7.6, median 5 slides per case).
On review, 33 patients were found to have earlier undiagnosed
invasive carcinoma in the sections submitted (usually small and
low grade) and were excluded from analysis. Twenty patients were
not proven to have DCIS; in these cases, additional material was
sought from the originating laboratory and reviewed, but no DCIS
was identified in any of the material sent.
Sections were unavailable, or could not be retrieved, from 300
patients; these were not from any particular unit, coordinating
centre or trial arm. Incomplete review data were available on a
further 117 patients (e.g. the section submitted bore insufficient
DCIS for a complete assessment). A total of 1224 (72.3%) patients
had full data from histological review available on DCIS size,
histological grade/sub-type, presence and degree of comedo-type
necrosis, presence and degree of inflammation and excision status
and were included in the present analyses (Table 1). Accurate
review of the presence or absence of microinvasion was felt to be
too error prone for meaningful analysis; some cases had the
original sections submitted for review, but from other cases, new
sections had been cut and submitted for re-evaluation. Never-
theless, only 16 of the 1224 cases in this series had definite
microinvasion and a further 42 had ‘possible’ microinvasion in the
original histology report. This feature was related to size of DCIS
lesion, but not, perhaps surprisingly, to the grade of DCIS (data
not shown).
Analysis for treatment arms was repeated, using the sub-set of
cases with full pathological data from this review, to confirm that
the results were not significantly different from the whole group
analysis presented earlier (UK Coordinating Committee on Cancer
Research Ductal Carcinoma in situ Working Party, 2003).
One hundred and fifty four of the 1224 cases reviewed (12.6%)
developed recurrence of disease either DCIS or invasive carcinoma
in the ipsilateral breast. Ninety nine (64%) developed recurrent
DCIS and 55 invasive disease, comparable with the results in
analysis of the overall trial.
Univariate analyses and distribution of features of DCIS are
shown in Table 1. The DCIS was found to be of high cytonuclear
grade (National Pathology Co-ordinating Group, 2005) in 74.6% of
cases (n¼913), 18.4% were of intermediate grade and only 7.0% of
cases (n¼225) were of low cytonuclear grade (n¼86). Breakdown
by Van Nuys grade (Silverstein et al, 1995) showed that in addition
to the 913 patients (as above) with high-grade disease (74.6%), 212
had DCIS, which was non-high grade but in which necrosis was
present (17.3%), and 99 patients had non-high-grade DCIS without
necrosis (8.1%). Comedo-type necrosis, to a greater or lesser
extent, was present in all, but 117 cases (90.4%) in this series of
screen-detected DCIS.
All of the systems of grading of DCIS applied showed a
significant association with recurrence of ipsilateral DCIS or
invasive disease, as did the predominant growth pattern/architec-
ture of the disease. Patients with a solid morphology as the main
architectural pattern of DCIS had a 15.2% recurrence rate
compared with 14.3% of those with micropapillary DCIS and only
7.3% of those with predominantly cribriform DCIS. The presence
or absence of comedo-type necrosis and the presence of associated
chronic inflammation was also associated with increased risk of
recurrence of DCIS or progression to invasive cancer in the
ipsilateral breast (Table 1).
Intragrade analysis showed that the pure comedo-type cases
(n¼483, 39.5%) fared particularly poorly. This grading system
recognised a large group of cases in this trial as ‘non-pure
comedo’ type disease (51.0%).
Re-analysis of cytonuclear grade with the inclusion of an
additional particularly aggressive ‘pure comedo’ group was,
therefore, undertaken. Using the definitions applied in this review,
this latter group had (i) high-cytonuclear-grade DCIS, (ii) 450%
solid architecture and (iii) 450% of the ducts bore central
confluent comedo-type necrosis. This resulted in a new four-tiered
system: low (low cytonuclear grade (7.0% cases)), intermediate
(intermediate cytonuclear grade (18.4% of cases), high (high
cytonuclear grade, but not pure comedo (i.e. not predominantly
solid architecture or o50% ducts bore necrosis) (35.1%)) and very
high (high-grade DCIS of 450% solid architecture and 450%
ducts bearing comedo-type necrosis (39.5% of cases)). This novel
classification system showed a strong relationship with develop-
ment of ipsilateral recurrence (Table 2a), both overall and
separately for DCIS and invasive disease (Figures 1–3). This new
classification system, retained significance across the range of sizes
of disease (although numbers in the groups are by necessity
smaller). Even, for example, for those lesions 10–19mm in size,
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sthe new system could distinguish a group of patients with very
high-grade disease who had a significantly higher risk of
developing ipsilateral recurrence of DCIS or invasive carcinoma
over the remainder of those with cytonuclear high-grade DCIS
(Table 2b).
The maximum dimension of DCIS (the larger size from either
original histology report or histological review) ranged from 0.5 to
82mm (median 14.5mm). There were 368 patients with DCIS
o10mm in size (30.1%), 575 (46.9%) had DCIS measuring
10–19mm and 268 patients (21.9%) had lesions X20mm. The
total size of DCIS could not be accurately determined in 13 patients.
Univariate analysis showed that larger DCIS size (X20mm) was
associated with a higher risk of ipsilateral recurrence.
Despite the inclusion criteria requiring ‘complete excision’, this
was not quantified in the original trial protocol. Defining complete
excision as 1mm or more distance to the nearest margin for this
analysis, it was found that 196 patients (16.0%) had incompletely
excised disease. In 182 patients, the completeness of excision was
uncertain (14.9%). The majority (69.1%, n¼846) had DCIS that
was completely excised X1mm; this was associated with a lower
risk of ipsilateral recurrence of disease (DCIS or invasive). No
association was seen between completeness of excision and DCIS
size, or with grade of DCIS (data not shown).
An absolute measurement of the distance to the margins in mm
was available in 637 cases, from the original report or the
histological review. The range of distance to the surgical margins
was 0–25mm, the median was 1.5mm and the mean 2.8mm. Some
cases of DCIS were assessed as excision ‘uncertain’ as a categorical
variable, as described above, for example when there was
disagreement between the original histology report and review.
For this reason, there was a greater number of cases with a margin
measurement of o1mm (n¼269; 42.2%) than were classified as
incompletely excised, as described above (n¼196). Of the group
with assessable margin width, 214 (33.6%) had disease between
1 and o5mm from the margin and 154 (24.2%) had disease 5mm
or more from an inked radial margin of excision. Only 29 patients
(4.5%) had disease 410mm from the margin. Analysis of margin
distance (sub-grouped either as o1mm; 1 to o2mm; 2 to
Table 2a New grading system – recurrence of ipsilateral DCIS or invasive carcinoma
Feature Category No. cases No. events HR (95% CI) v
2 for trend, P-value
Recurrence of ipsilateral DCIS or invasive
Grading system, four tier Low 86 6 0.42 (0.18–0.95) 22.11
Intermediate 225 13 0.33 (0.19–0.60) P¼0.0001
High 430 47 0.62 (0.43–0.88)
Very high 483 88 1.00
a
New grade, three tier Low/intermediate 311 19 0.36 (0.22–0.58) 21.91
High 430 47 0.62 (0.43–0.88) P¼0.0001
Very high 483 88 1.00
a
Recurrence of ipsilateral DCIS
Grading system, four tier Low 86 4 0.44 (0.15–1.20) 15.42
Intermediate 225 7 0.28 (0.12–0.62) P¼0.002
High 430 32 0.66 (0.43–1.02)
Very high 483 56 1.00
New grade, three tier Low/intermediate 311 11 0.32 (0.16–0.61) 14.97
High 430 32 0.66 (0.43–1.02) P¼0.0006
Very high 483 56 1.00
Recurrence of ipsilateral invasive
Grading system, four tier Low 86 2 0.41 (0.10–1.72) 6.67
Intermediate 225 6 0.46 (0.19–1.11) P¼0.08
High 430 14 0.53 (0.28–0.99)
Very high 483 32 1.00
New grade, three tier Low/intermediate 311 8 0.45 (0.21–0.98) 6.65
High 430 14 0.53 (0.28–0.99) P¼0.04
Very high 483 32 1.00
Abbreviations: CI¼confidence interval; DCIS¼ductal carcinoma in situ;H R¼hazard ratio.
aBaseline category. NB: There is one ipsilateral event for which it is unknown whether
the recurrence was DCIS or invasive.
Table 2b New grading system for size groups – recurrence of ipsilateral DCIS or invasive carcinoma
Feature Category No. cases No. events HR (95% CI) v
2 for trend, P-value
Tumour size o9mm
New grade, three tier Low/intermediate 132 3 0.21 (0.05–0.71) 8.57
High 108 9 0.75 (0.32 – 1.71) P¼0.011
Very High 128 15 1.00
a
Tumour size 10–19mm
New grade, three tier Low/intermediate 116 9 0.43 (0.21–0.90) 8.77
High 222 23 0.55 (0.33–0.91) P¼0.01
Very high 237 45 1.00
a
Tumour size 420mm
New grade, three tier Low/intermediate 62 7 0.46 (0.31–1.15) 4.65
High 94 14 0.46 (0.20–1.06) P¼0.09
Very high 112 28 1.00
a
Abbreviations: CI¼confidence interval; DCIS¼ductal carcinoma in situ;H R¼hazard ratio.
aBaseline category.
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so5mm; 5mm or more) showed that the distance of disease to the
margin was a significant predictor of ipsilateral recurrence of
disease (DCIS or invasive) (Table 3). The DCIS excised by X5mm
had approximately half the risk of ipsilateral recurrence compared
with DCIS excised by o1mm.
The presence of chronic inflammation was related to recurrence
of ipsilateral disease (Table 1). Of note, this was particularly
associated with an increase in progression to ipsilateral invasive
disease recurrence rather than recurrent DCIS. Those cases
without chronic inflammation had a hazard ratio (HR) for
ipsilateral invasive disease recurrence of 0.27 compared with cases
in which an inflammatory cell infiltrate was identified. For DCIS
recurrence, in the absence of chronic inflammation, the HR was
0.58. Of note, this feature was very commonly present to some
degree (76% of cases) and was related to the grade of DCIS (seen in
21%, 55% and 86% of cytonuclear grades 1, 2 and 3, respectively,
w
2¼250.0, Po0.001), but was independent of grade of DCIS
(and also the new classification system) in multivariate analysis
(Table 4).
Multivariate analysis including the new grading four-tier system
for DCIS, the receipt of RT, tumour size and completeness of
excision is shown in Table 4; the HR of the new very high grade
was 2.77 for any ipsilateral recurrence when compared with
low- and intermediate-grade DCIS. Multivariate analysis also
confirmed that RT reduced the risk of ipsilateral DCIS and
invasive recurrence by approximately one-third (HR¼0.34,
CI¼0.23–0.52) in this large sub-set of pathologically reviewed
cases from the main trial. Increasing DCIS size was also of
independent significance.
DISCUSSION
Many of the cases did not have what would now be considered the
minimum dataset of features for DCIS reported in the original
laboratory (Lester et al, 2009); all the histological features
presented here are derived from the central histopathology review.
Such review of any large multicentre trial is fraught with
difficulties, including the retrieval of histological sections from
a large number of different laboratories. This is particularly
problematic for trials of DCIS, as more than one surgical
procedure is more frequently undertaken than for invasive breast
carcinoma. In total, 72.3% of the cases had material reviewed.
The determination of completeness of excision of DCIS can be
difficult for the primary reporting pathologist, but especially in a
central review; for this reason, this feature has not been included in
the analysis in many papers (de Mascarel et al, 2000; Ottensen
et al, 2000). We report details of margin status and distance to
margins in the present analysis, but would note that the evaluation
of this feature and, in particularly, the measurement of distance
to margins cannot be considered precise. Despite this, both
completeness of excision as a categorical variable and the distance
to margins were found to be of independent significance in
predicting for ipsilateral recurrence of disease, highlighting again
the significance of this feature in clinical management of DCIS.
No defined margin distance was required for inclusion into this
randomised clinical trial. Pragmatically, complete excision was
defined as X1mm in this pathological review analysis; many
will claim this cutoff is too small. The margin width desirable
for adequate treatment of pure DCIS remains a topic of major
controversy with some of the opinion that the margin should
simply be ‘tumour free’ (Fisher et al, 1993). It has been suggested
that a 2mm margin is sufficient if RT is also given (Kell and
Morrow, 2005), but others recommend that a larger width of
tumour-free tissue is appropriate and have shown an increasing
HR for local recurrence with decreasing margin clearance in
patients with DCIS treated by excision alone (MacDonald et al,
2005). We have found that complete excision (X1mm) was
associated with a lower risk of local recurrence of ipsilateral
disease, but the present analysis does not unequivocally assist in
distinguishing what margin width is optimal (Table 3).
The presence of chronic inflammation was found to be a
predictor of a higher risk of ipsilateral recurrence of invasive
disease, but not of recurrent DCIS. This was related to, but
statistically independent of, cytonuclear grade. The presence of
chronic inflammation may be associated with invasive and
Years since randomisation
0 5 10
0.7
0.8
0.9
1
Low
Intermediate
High
Very high HR = 1.56 (1.27 – 1.91)
P <0.0001
Figure 1 Recurrence of ipsilateral DCIS or invasive carcinoma by new
grading system for DCIS.
Years since randomisation
0 5 10
0.7
0.8
0.9
1
Low
Intermediate
High
Very high
HR = 1.57 (1.21– 2.03)
P = 0.0003
Figure 2 Recurrence of ipsilateral DCIS by new grading system
for DCIS.
Years since randomisation
0 5 10
0.7
0.8
0.9
1
Low
Intermediate
High
Very high
HR = 1.49 (1.06 –2.10)
P = 0.02
Figure 3 Recurrence of ipsilateral invasive carcinoma by new grading
system for DCIS.
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sangiogenic factors, a local milieu, which facilitates invasion
through the basement membrane. An association with the
development of invasive carcinoma thus seems plausible, but
the association with recurrence independent of features such as
completeness of excision is difficult to explain and clearly requires
further investigation. Further evaluation of the nature of the
chronic inflammation was not possible using the routinely stained
sections in this review, but seems warranted.
Patient age was significantly associated with disease recurrence
in univariate analyses (P¼0.05), but this was not retained in the
multivariate model. However, the majority of patients recruited to
the trial had DCIS detected through the UK National Health
Service Breast Screening Programme available to all women aged
50–64 years (at that time). Thus, only 92 of the 1224 women in this
analysis were p50 years of age, so comment cannot be made
regarding young patient age and risk of recurrence from this
clinical trial.
The distribution of cytonuclear grade of the DCIS in this UK
trial is different to that in other series such as the EORTC 10853
trial; in the latter study, only 40% of cases were poorly
differentiated, 28% were moderately differentiated and 32% were
well differentiated (Bijker et al, 2001). In comparison, the
proportion of DCIS of high grade in the present series is large
(74.6%). Although this is likely, at least in part, to be a reflection of
the era in which the patients were recruited to the trial, high-grade
DCIS remains the commonest form identified in the United
Kingdom. In the Sloane Project/UK audit of screen-detected DCIS,
62% of 1101 DCIS, in which grade was recorded, were of high
grade (Thomas et al, 2008). Although difficulties regarding the
reproducibility of grade of DCIS between pathologists have been
described (Ellis et al, 2006), in the present review, all cases were
examined by one pathologist, reducing this element of variation.
DCIS is a heterogeneous disease morphologically, immuno-
histochemically and genetically (Patchefsky et al, 1989; Bobrow
et al, 1994; Meijnen et al, 2008; Vincent-Salomon et al, 2008) and
sub-typing can identify lesions with differing risks of progression
and recurrence. In this study, risk of ipsilateral recurrence was
related to sub-type of disease, using many of the grading systems
described (Holland et al, 1994; Poller et al, 1994; Silverstein et al,
1995; National Pathology Co-ordinating Group, 2005), as shown
in Table 1, or indeed the older historical method of sub-typing
based on architecture and cell size. The presence of comedo-type
necrosis also predicted outcome, as shown in other studies
(Fisher et al, 1995, 1999b; Silverstein et al, 1996). Growth
pattern/architecture also reflected risk of recurrence, as shown in
the EORTC DCIS trial (Bijker et al, 2001). In the present large
series reviewed by a single breast pathologist, many of the earlier
described prognostic features of DCIS showed a relationship with
risk of ipsilateral recurrence of disease; the question then remains
as to which of these features is/are most valuable?
In this study, we have identified a group of patients with a
particularly poor outcome, which has not been shown earlier. The
novel finding in this series is that those women who had DCIS not
only of high nuclear grade, but also of pure (450%) solid
architecture with extensive necrosis (in 450% of ducts) had a
significantly worse outcome than those with a high cytonuclear
grade alone. Thus, the division of DCIS into low-, intermediate- and
high-grade forms, as applied in present systems of classification
(National Pathology Co-ordinating Group, 2005; Lester et al, 2009),
may not be optimal. The relatively small proportion of disease of
low or intermediate grade, and the few events in these groups,
makes it difficult to draw definitive conclusions from the present
series, but patients with low- or intermediate-grade DCIS fared
similarly well. Of note, low- and intermediate-grade DCIS have also
been shown to have similar immunohistochemical profiles, distinct
from that of high-grade disease (Meijnen et al, 2008).
The system we describe suggests that DCIS is better classified by
an alternative three group system: (i) a group of low- and
intermediate-cytonuclear-grade disease, (ii) high-nuclear-grade
DCIS of non-solid architecture or with o50% ducts bearing
necrosis and (iii) high-nuclear-grade DCIS with extensive
confluent comedo-type necrosis (450% ducts) and with solid
architecture. These groups have ipsilateral recurrence rates of
Table 4 Multivariate analysis for all ipsilateral recurrent events and for
recurrence of ipsilateral invasive disease
Recurrence of
all ipsilateral
disease (DCIS
or invasive)
Recurrence of
ipsilateral
invasive
carcinoma
Covariate
No.
cases HR 95% CI
No.
cases HR 95% CI
New grading system
Low and intermediate 310 1
a 309 1
a
High 424 1.69 0.99–2.89 423 0.86 0.35–2.11
Very high 477 2.77 1.69–4.57 476 1.46 0.65–3.31
XRT received
No XRT 776 1
a 774 1
a
XRT 435 0.34 0.23–0.52 434 0.52 0.27–0.98
Tumour size
0–0.9cm 368 1
a 366 1
a
1.0–1.9cm 575 1.67 1.07–2.59 574 1.89 0.89–3.99
X2cm 268 2.67 1.66–4.30 268 1.89 0.80–4.49
Excision
Complete 838 1
a 835 1
a
Incomplete 192 1.47 0.98–2.22 192 1.01 0.46–2.21
Uncertain 181 1.82 1.21–2.73 181 2.35 1.27–4.37
Inflammation
Absent 294 1
a
Present 914 3.11 1.06–9.13
Abbreviations: CI¼confidence interval; DCIS¼ductal carcinoma in situ;H R¼hazard
ratio; XRT¼radiotherapy.
aBaseline category.
Table 3 Margin distance as a predictor of outcome
End point Distance to margin
a No. cases No. events HR (95% CI) v
2 for trend, P-value
Ipsilateral DCIS or invasive recurrence 0–o1mm 269 47 1.00
b 4.93
X1–o2mm 71 6 0.47 (0.20–1.11) P¼0.03
X2–o5mm 140 20 0.88 (0.52–1.48)
X5mm 157 13 0.46 (0.25–0.86)
Ipsilateral DCIS or invasive recurrence 0–o1mm 269 47 1.00 4.98
X1mm 368 39 0.61 (0.41–0.94) 0.03
Abbreviations: CI¼confidence interval; DCIS¼ductal carcinoma in situ;H R¼hazard ratio.
aBaseline category.
bThe smaller of the measurement (i) from the original histology
report (if noted) or (ii) from the histological review of slides was used for analysis, unless there was a clear discrepancy when the margin distance was recorded as not assessable.
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sDCIS or invasive disease of 6.1%, 10.9% and 18.2%, respectively.
Although this proposed system of classification clearly requires
further validation in other series, it may potentially aid in the
recognition of more clinically relevant groups of patients with
DCIS, namely women with low-risk disease who may not require
further adjuvant therapy to the breast and a group with a
particular high risk of recurrence who may benefit from maximal
local therapy.
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